Aurobindo Pharma's Subsidiary Gets EU Nod for Biosimilar

Aurobindo Pharma announced that its step-down subsidiary, CuraTeQ Biologics, has received marketing authorization from the European Commission for Dyrupeg™, a biosimilar of pegylated filgrastim. This approval follows a positive recommendation from the European Medicines Agency earlier in January 2025.